Home > Neurology > EAN 2020 > Epilepsy > Prevalence of autoantibodies in epilepsy almost 10%

Prevalence of autoantibodies in epilepsy almost 10%

At clinics in the UK, 9.3% of epilepsy outpatients had potentially pathogenic autoantibodies. The proportion of antibody-positive patients was similar across patients with new-onset focal epilepsy, drug-resistant epilepsy, and seizure-free epilepsy.

The prevalence of autoantibodies among people with epilepsy is not clear; rates between 5-80% have previously been reported. By determining the prevalence of largely pathogenic antibodies in prospectively recruited outpatients with new-onset focal epilepsy, drug-resistant epilepsy, and seizure-free epilepsy, British researchers aimed to provide a prevalence rate that is generalisable to the broader population of epilepsy patients [1]. They screened collected serum on live cell-based assays for neuronal-surface antibodies (NSAs) to LGI1, CASPR2, contactin-2, DPPX, antibodies to intracellular GAD65, and the GABAA, GABAB, glycine, and NMDA receptors. Overall, autoantibodies were detected in 51/546 (9.3%) epilepsy ...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on